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ABSTRACT
TBLR1/TBL1XR1, a core component of the nuclear receptor corepressor (NCoR)
complex critical for the regulation of multiple nuclear receptors, is a transcriptional
coactivator of androgen receptor (AR) and functions as a tumor suppressor when
expressed in the nucleus in prostate. Subcellular localization of a protein is critical
for its function, and although TBLR1, as a transcriptional cofactor, has been primarily
viewed as a nuclear protein, many cells also express variable levels of cytoplasmic
TBLR1 and its cytoplasmic specific functions have not been studied. Prostate cancer
(PCa) cells express moderately higher level of cytoplasmic TBLR1 compared to benign
prostate cells. When comparing androgen-dependent (AD) to androgen-independent
(AI) PCa, AI cells contain very high levels of TBLR1 cytoplasmic expression and
low levels of nuclear expression. Overexpression of cytoplasmic TBLR1 in AD cells
inhibits apoptosis induced by androgen deprivation therapy, either in an androgen free
condition or in the presence of bicalutamide. Additionally, we identified a cytoplasmic
specific isoform of TBLR1 (cvTBLR1) approximately 5 kDa lower in molecular weight,
that is expressed at higher levels in AI PCa cells. By immunoprecipitation, we
purified cvTBLR1 and using mass spectrometry analysis combined with N-terminal
TMPP labeling and Edman degradation, we identified the cleavage site of cvTBLR1
at amino acid 89, truncating the first 88 amino acids of the N-terminus of the full
length protein. Functionally, cvTBLR1 expressed in the cytoplasm reduced apoptosis
in PCa cells and promoted growth, migration, and invasion. Finally, we identified a
nuclear export signal sequence for TBLR1 cellular localization by deletion and sitedirected mutagenesis. The roles of TBLR1 and cvTBLR1 provide novel insights into
the mechanism of castration resistance and new strategies for PCa therapy.
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INTRODUCTION

including nuclear localization signals (NLS) and nuclear
export signals (NES). Common NLS sequences contain
arginine and lysine, and NES sequences are leucine rich,
however these cases do not appear to be universal [21, 22].
In this study we characterize the expression and
function of cytoplasmic TBLR1, which is found in a
55 kDa full length form and, in PCa, in a 50 kDa isoform
also. We found increased cytoplasmic TBLR1 in CRPC
and also identified a post-translational cleaved variant of
TBLR1 localized only in the cytoplasm that is also higher
in CRPC. We found that TBLR1 when localized in the
cytoplasm inhibits apoptosis induced by androgen ablation
in PCa cells. Additionally, we identified a nuclear export
sequence within the protein necessary for its sub-cellular
compartmentalization. This study may provide insight to
develop effective targets for the treatment of CRPC.

Prostate cancer (PCa) is an exceedingly prevalent
cancer and is the second leading cause of cancer related
death of men in the US [1]. It has long been known that
androgens are critical for PCa growth and androgen
ablation therapy is still the mainstay of treatments for
patients with metastatic PCa. Although initially effective,
these cancers inevitably recur as castration resistant
prostate cancer (CRPC) for which there is still no reliable
treatment. Deaths from PCa are primarily due to the
development of castration resistant metastatic disease.
Many mechanisms of CRPC have been proposed and
studied, including but not limited to increased Androgen
Receptor (AR) expression, crosstalk with other signaling
pathways, AR splice variants, and variable AR cofactor
expression [2–5].
Transducin beta like related 1 (TBLR1), also
known as TBL1XR1, is a core component of the nuclear
receptor corepressor (N-CoR) and is a silencing mediator
of retinoic acid and thyroid receptor (SMRT) complex
[6, 7]. A secondary isoform of TBLR1 (TBLR1β) has been
previously identified, formed from alternative splicing
creating a variable C-terminus and a slightly larger protein
of about 60 kDa [8]. As an intrinsic component of these
corepressor complexes, TBLR1 has essential functions
both as a corepressor and a coactivator of multiple nuclear
receptors [9, 10]. Additionally, TBLR1 and the closely
related TBL1X are necessary for activation of Wnt target
genes [11]. TBL1X plays an important role in protecting
beta catenin from degradation in the cytoplasm allowing
for transcription of its targets genes [12]. Overexpression
of TBLR1 inhibits growth in 293T and Jurkat cells and
is involved in degradation of the anti-apoptotic protein
BCL-3 [8, 13]. TBLR1 is a ubiquitously expressed
protein [14]. Immunohistochemical data shows TBLR1 as
primarily a nuclear protein in normal prostate but shows
reduced nuclear expression in PCa [15]. TBLR1 is also
a strong coactivator of AR in prostate cancer, leading
to selective activation of growth suppressive AR target
genes and tumor suppression. In contrast to the reduced
expression of TBLR1 in PCa, expression of TBLR1 is
upregulated in breast, colon, esophageal squamous cell
and nasopharyngeal carcinomas (NPC) and is a potential
prognostic marker for aggressive cervical cancer [16–18].
Overexpression of TBLR1in NPC cells causes reduced
sensitivity to cisplatin-induced apoptosis [18].
Nuclear transport is critical for controlling
localization and proper function of proteins. Many proteins
exhibit different functions based on their post-translational
modifications and cellular compartmentalization. The AR
coactivator p44/MEP50 displays a tumor suppressor role
in the nucleus but promotes PCa growth and prostate
development when expressed in the cytoplasm [19].
Transport of proteins across cellular compartments is
regulated at several protein and cellular levels [20],
www.impactjournals.com/oncotarget

RESULTS
Reduction of apoptosis by full length cytoplasmic
TBLR1 (cTBLR1) under androgen deprivation
Previously our lab showed that TBLR1 was
expressed as both nuclear and cytoplasmic protein [15]. In
PCa cells, nuclear expression of TBLR1 was significantly
reduced in comparison to benign prostate cells. In this
study we compared cytoplasmic expression of TBLR1
and its function between androgen-dependent (AD) PCa
cells and androgen-independent (AI) PCa cells. When
comparing TBLR1 levels by western blot between AD
LNCaP PCa cell lines and two AI PCa cell lines, LNCaPAI and PC-3, we found increased total level of TBLR1
in the AI cells (Figure 1A). To determine the subcellular
localization of the increased TBLR1 in AI cancer cell lines
compared to AD cancer cells, we performed western blot
analyses with fractionated nuclear and cytoplasmic cell
lysates. We found that the increased level of TBLR1 in AI
cancer cell lines was due to increased cytoplasmic TBLR1
(Figure 1C, 1D).
Previously our lab showed that overexpression of
nuclear TBLR1 in AD LNCaP cells inhibited growth in
an androgen-dependent manner by cell cycle arrest but
this overexpression had no effect on apoptosis [15]. To
test the function of cytoplasmic TBLR1, we created stable
LNCaP cell lines overexpressing TBLR1 in the cytoplasm
utilizing a fusion construct of the nuclear export sequence
(NES) (MLQKKLEELE) to the N-terminus of TBLR1.
We confirmed overexpression and cytoplasmic localization
of TBLR1 in these cells by western blot of total lysate
(Figure 1E) and fractionated lysate (Supplementary
Figure 1A). LNCaP cells require androgens for survival
and in their absence, these cells undergo apoptosis [23].
LNCaP NESTBLR1 cells exhibited reduced cell death
visually (Figure 1G) in androgen free media compared to
control cells (Figure 1F). Next, we performed Caspase 3/7
activity assays to test the effect of cytoplasmic TBLR1
39557
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on apoptosis in androgen-free and regular media with
and without bicalutamide, an anti-androgen medication.
LNCaP NESTBLR1 cells showed significant reduction
of Caspase 3/7 activity after 48 hours in androgen-free
medium (Figure 1H). We also observed a significant
reduction of Caspase 3/7 activity after 30 hours in 150 µm
anti-androgen bicalutamide media in LNCaP NESTBLR1
cell (Figure 1I). We confirmed reduced apoptosis in
androgen-free conditions and bicalutamide-treated cells
in LNCaP NESTBLR1 cells compared to LNCaP pBabe
cells by TUNEL assay. Quantification of TUNEL-positive
cells showed approximately 2.5 fold reduction for
LNCaP NESTBLR1 cells in both conditions (Figure 1J).
Representative pictures showing reduced TUNEL staining
in both conditions in LNCaP NESTBLR1 cells are shown
in Figure 1K–1L. Notably, we also tested cell proliferation
and migration/invasion ability between LNCaP pBabe
and LNCaP NESTBLR1 cells and we did not observe any
difference (data not shown). The reduction in apoptosis
by NESTBLR1 in regular medium by both assays was
not statistically significant (data not shown). In cell
proliferation, migration and invasion assays, NESTBLR1
did not show statistically significant differences when
compared to control.

specifically immunoprecipitated cvTBLR1 with only small
amounts of full length TBLR1 present. We next prepared
large-scale immunoprecipitation preps in PC-3 cells
using either Antibody #1 or Antibody #2 for purification.
Pulldown of cvTBLR1 was first confirmed by western
blot (Figure 2B). Antibody #1 primarily pulled down
cvTBLR1 and post-TBLR1 IP lysate showed reduced
levels of cvTBLR1 compared to post-IgG IP, confirming a
very efficient capture. Colloidal coomassie blue stain was
performed on purified protein to be processed by mass
spectrometry (MS) analysis (Supplementary Figure 1B).
Purified cvTBLR1 and full length TBLR1 were
analyzed by tryptic digestion and MS to identify and
compare known peptide sequences present. cvTBLR1
sequence lacked evidence of the first 100 amino acids
suggesting this region of full length TBLR1 could be
lacking in this isoform (Figure 2C). No peptides from
the first 100 amino acids were detected by MS in three
separate cvTBLR1 purifications (data not shown). We next
performed MS analysis of purified full length TBLR1 to
determine if detection of these peptides was not readily
detected by our mass spectrometer. This analysis of
full length TBLR1 revealed the presence of additional
peptides up to AA 28, supporting the conclusion that this
N-terminal region was lacking in cvTBLR1 (Figure 2D).
To identify the exact location of the cleavage to form
cvTBLR1, we next utilized in-gel TMPP N-terminus
labeling of purified cvTBLR1 prior to tryptic digestion
followed by MS analysis. MS analysis can recognize the
presence of the TMPP label and identify the N-terminus
sequence of the original protein. We found PDVVQ to
be the N-terminus labeled peptide with P corresponding
to amino acid 89 of TBLR1 (Figure 2E). We confirmed
these findings by N-terminal Edman degradation of
purified cvTBLR1 that also found P89 as the N-terminus
of cvTBLR1 (Figure 2F). This N-terminus region
contains the LisH domain critical for histone binding for
transcriptional corepression and the F-box like domain for
transcriptional coactivation (Figure 2G, 2H). Since AA88
of TBLR1 is a methionine, there was a strong possibility
that cvTBLR1 could be the product of alternate translation.
To test for alternate translation, we created a mutant
construct of TBLR1 altering the methionine at amino
acid 88 into an alanine (M88A) and stably transfected
the mutant and control plasmid into 293T cells. In both
conditions we identified increased cvTBLR1 which
rules out alternate translation as a method of cvTBLR1
production (Figure 2I). Additionally, there is no evidence
of an alternate mRNA spliced variant of this size. Together
this data suggests that cvTBLR1 could be a proteolytic
cleavage of full length TBLR1 or a potential alternate
translation product.
We next tested the function of cvTBLR1 in prostate
cancer cells. We created a fusion construct in the pBabe
retroviral vector of nuclear export sequence (NES)cvTBLR1 (AA89-514 of TBLR1) and stably transfected

Identification and function of 50 kDa
cytoplasmic-specific TBLR1 isoform
In addition to full length TBLR1, we identified
a faster migrating protein band recognized by TBLR1
antibody that runs at approximately 50 kDa (Figure 1A).
We consistently observed cvTBLR1 across multiple cell
lines including LNCaP-AI, C4-2B and VCaP. To confirm
this second observed band as a variant of TBLR1 protein,
we transfected LNCaP-AI cells with specific siRNA for
TBLR1. TBLR1 specific siRNA reduced expression
of both full length and the faster migrating variant.
Conversely, overexpression of full length TBLR1 cDNA
by transfection into cells also led to increased cvTBLR1
by western blot (data not shown). These data confirm the
50 kDa band is a specific TBLR1 isoform (cvTBLR1)
(Figure 1B). We also found that cvTBLR1 was only
expressed in the cytoplasm and was significantly increased
in AI cells (Figure 1C). Over expression of NES-TBLR1
also leads to increased cvTBLR1 levels in the cytoplasm
(Supplementary Figure 1A).
In order to isolate and purify cvTBLR1 for analysis
we tested different commercial TBLR1 antibodies
for TBLR1 immunoprecipitation to identify potential
capture antibodies specific for cvTBLR1. We used three
different TBLR1 specific antibodies and found that each
antibody selectively pulls down a single form of TBLR1
(Figure 2A). Interestingly, all three of these antibodies
recognize both forms by western blot (data not shown).
Antibody #1, a monoclonal antibody designed from
peptide sequence AA 81-179 of the 514 AA protein
www.impactjournals.com/oncotarget
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Figure 1: Expression of full length cytoplasmic TBLR1 (cTBLR1) and protease cleaved cytoplasmic variant of TBLR1
(cvTBLR1) in prostate cancer cells. (A) Relative total expression of TBLR1 and cvTBLR1 in androgen-dependent LNCaP cells

compared to androgen-independent LNCaP-AI and PC-3 cells. (B) Confirmation of faster migrating band (cvTBLR1) as a TBLR1 variant
by knockdown with TBLR1 specific siRNA in LNCaP-AI cells. (C) Relative expression and localization of TBLR1 and cvTBLR1 in
prostate cancer cells by western blot of fractionated lysates. (D) Quantification of fractionation western blot comparing localization and
relative expression of TBLR1 and cvTBLR1 in prostate cancer cells. (E) Overexpression of cytoplasmic TBLR1 using nuclear export
sequence (NES) fused TBLR1 construct to create LNCaP –NESTBLR1 cells. (F) LNCaP pBabe cells after 6 days in hormone free media.
(G) LNCaP NESTBLR1 cells after 6 days in hormone free media. (H) Caspase 3/7 luciferase assay measuring apoptosis in LNCaP
pBabe and LNCaP NESTBLR1 cells in hormone free media. (I) Caspase 3/7 luciferase assay measuring apoptosis in LNCaP pBabe and
LNCaP NESTBLR1 cells in 150 µM bicalutamide media. (J) Quantification of the percentage of TUNEL-positive cells of LNCaP pBabe
vs. LNCaP NESTBLR1 cells in hormone free media or 150 µM bicalutamide media. (K) TUNEL staining on LNCaP control vs. LNCaP
NESTBLR1 cells in androgen free and androgen media with (L) 150 µM bicalutamide treatment.

it into LNCaP prostate cancer cells (Figure 3A). We
tested the effect of cvTBLR1 on apoptosis in these
cells by a Caspase 3/7 assay and found significant
reduction of Caspase 3/7 activity in androgen-free and
bicalutamide media signifying a reduction in apoptosis
(Figure 3B, 3C). We confirmed these findings by TUNEL
assay in androgen-free media and bicalutamide media
(Figure 3D, 3E). Interestingly and in contrast to full
length TBLR1, overexpression of cvTBLR1 also led
to a significant increase in cellular proliferation over a
6-day growth assay (Figure 3F). We compared migration
and invasion ability by measurement of cells traversing
either an uncoated porous membrane (migration) or
matrigel-covered membrane (invasion) using serum as a
chemoattractant. We found significantly more migrating
and invading cells with overexpression of cvTBLR1
(Figure 3G, 3H).

used site-directed mutagenesis to alter Leucine 81 (mut1)
or Leucine 83 (mut2) or both (mut3) to alanine. We cloned
these constructs into a pCDNA-GFP vector to visualize
localization by confocal microscopy after transient
transfection into 293T cells (Figure 4A).
After transfection, cells were counted as nuclear,
cytoplasmic, or both (equal expression). Figure 4A
summary shows the predominant localization for
each construct. Cells transfected with N2 construct
expressing amino acid (AA) 1–86 of the 514 AA
wild type (WT) TBLR1 showed strong cytoplasmic
expression (Figure 4B, 4F). Cells transfected with N7
(AA1-80), however, showed stronger nuclear expression
(Figure 4C, 4G). Interestingly, although endogenous
TBLR1 is expressed in both the cytoplasm and nucleus
of cells, overexpression of GFP-TBLR1 shows very
strong cytoplasmic expression (Figure 4D, 4J). Since
NES sequences are often leucine-rich [22] and there are
two leucines within the AA81-86 region, we used sitedirected mutagenesis to mutate each of these leucines in
the full length TBLR1 (mut1, mut2, mut3) and transfected
these constructs into 293T cells. Transfection of mut1 no
longer showed strong cytoplasmic localization of WT,
but rather more equal distribution (Figure 4E, 4K). Mut2

Mutation analysis to identify nuclear export
sequences (NES) in TBLR1
To identify potential nuclear export sequences
(NES), we created a series of N-terminal (C1-C7) and
C-terminal (N1-N7) deletion mutants. Additionally, we
www.impactjournals.com/oncotarget
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Figure 2: Sequence identification of cvTBLR1. (A) Immunoprecipitation with three different TBLR1 specific antibodies to identify

antibody to purify cvTBLR1. (B) Large scale purification of cvTBLR1 using antibody #1 and full length TBLR1 using antibody #2 for
mass spectrometry (MS) sequencing. (C) TBLR1 sequence showing bold/highlighted sequences of peptides identified by MS from purified
cvTBLR1. (D) TBLR1 sequence showing bold/highlighted sequences of peptides identified by MS from purified full length TBLR1.
(E) Identification of N-terminal sequence of cvTBLR1 using TMPP labeled purified cvTBLR1 followed by MS sequence analysis.  MS/MS
spectrum of the doubly charged N-terminal peptide PDVVQTR of cvTBLR1 is shown, with the peptide sequence with annotation of the
matched ions above the spectrum. (F) Confirmation of N-terminus of cvTBLR1 by Edman degradation analysis of the protein, overlay plot
of the first five cycles. Y axis is millivolts.  Absorbance is measured at 269 nm.  Color code for the chromatogram matches the colors of the
text reporting the identified amino acids. (G) Diagram of conserved domains in full length TBLR1. (H) Diagram of cvTBLR1 lacking the
LisH and F-box domains of full length TBLR1 important for transcriptional regulation. (I) Overexpression of wildtype or mutated M88A
full length TBLR1 shows increased cvTBLR1 in both conditions.
www.impactjournals.com/oncotarget
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and mut3 also showed nuclear predominant localization
(Figure 4L– 4M). Quantification of the number of cells
with nuclear or cytoplasmic TBLR1 localization of
additional constructs is located in Supplementary Figure 2.
Together this data confirms AA81 and AA83 are important
residues for a strong NES in TBLR1.

process, since we have not observed a noticeable increase
in cvTBLR1 with transient overexpression of full length
TBLR1.
We were able to isolate cvTBLR1 by taking
advantage of an interesting observation that the TBLR1
antibodies we used to purify cvTBL1 exhibited different
specificities. While all TBLR1 antibodies detected
both forms on western blot, the TBLR1 antibody from
Abcam preferentially pulled down only cvTBLR1 by
immunoprecipitation. A possible explanation is that
cvTBLR1 has a tertiary structure different from that
of full length TBLR1, which makes certain epitopes
accessible for this antibody. As a result, this change
may be responsible for the localization and functions of
cvTBLR1. Mass spectrometric analysis of the TMPPlabeled purified cvTBLR1protein showed that it lacks the
first 88 amino acids of TBLR1. To support that cvTBLR1
is a product of proteolytic cleavage, we identified by
Edman degradation the N-terminus of cvTBLR1 as
PDVVQ, a peptide sequence located between amino acid
89 and 93 of TBLR1. This site is conserved in proteolytic
cleavage sites [28]. There is a methionine at amino acid 88
of TBLR1 suggesting that cvTBLR1 could be a product
of alternative translation. We created a TBLR1 mutant
that has an alanine replacing the methionine at amino acid
88, destroying the second translation initiation site. When
the mutant is expressed, the levels of full-length TBLR1
and cvTBLR1 are still both increased, which provides
strong evidence that cvTBLR1 is not due to alternative
translation.
Our previous study showed that overexpression
of nuclear TBLR1 inhibited LNCaP cell growth in
an androgen-dependent manner by cell cycle arrest
but had no effect on apoptosis [15]. In contrast, this
study demonstrates that overexpression of cytoplasmic
TBLR1, both full length and cvTBLR1, significantly
reduces apoptosis when measured by both fluorescent
Caspase 3/7 assays and Tunel experiments, consistent
with recent reports suggesting TBLR1 mediates
antiapoptotic effects [18]. Most significantly, the
inhibition of apoptosis is more dramatic in the androgendeprived condition, either in androgen-free medium
or in the presence of the anti-androgen, bicalutamide.
These findings suggest distinct functions of nuclear and
cytoplasmic TBLR1.
TBLR1 contains a conserved F-box-like domain
that associates with Skp1 in ubiquitin-dependent
protein degradation. In Drosophila Ebi, the homolog
of TBL1 and TBLR1, binds Tramtrack and promotes
its degradation [29, 30]. The canonical Wnt/βcatenin pathway plays an important role in prostate
tumorigenesis and is significantly mutated in CRPC.
The level of β-catenin is regulated by two mechanisms:
the adenomatous polyposis coli/Axin/glycogen synthase
kinase 3 beta-dependent degradation pathway and

DISCUSSION
TBLR1 was originally identified as an integral
component of the NCOR/SMRT co-repressor complex.
Subsequently, it was found that TBLR1 can also act
as a transcriptional activator for nuclear hormone
receptors and regulated transcription factors. TBLR1 is
overexpressed in several types of cancer and functions
as an oncogene by activation of important intracellular
signaling pathways including the Wnt-β-catenin
pathway and the nuclear factor-kappa (NF-kB) pathway
[11, 24]. TBLR1 expression has a positive correlation
with disease progression, tumor metastasis, and drug
resistance [16–18, 25–27]. Our previous study has
shown that TBLR1 is a transcriptional activator of AR
and its nuclear expression is significantly reduced in PCa
compared with benign prostate glands. Forced expression
of nuclear TBLR1 leads to androgen-dependent growth
suppression of prostate cancer cells in vitro and in vivo
by selective activation of androgen-regulated genes
associated with differentiation and growth suppression
[15]. In addition to its nuclear localization, TBLR1 can
also be a cytoplasmic protein. TBLR1 is predominantly
located in the cytoplasm of LNCaP-AI cells in complete
media but serum starvation induces its translocation into
nucleus. These findings suggest that cytoplasmic TBLR1
may play an important role distinct from that of nuclear
TBLR1. However, the functionality in most past TBLR1
studies did not clarify if the effects were due to nuclear or
cytoplasmic TBLR1.
In this study, we found that the total level of TBLR1
protein is increased in AI PCa cell lines compared to an
AD PCa cell line. For example, cytoplasmic TBLR1 is
expressed at a higher level in both LNCaP-AI and PC-3
cells compared to LNCaP cells. We also identified a novel
TBLR1 variant-cvTBLR1. It is exclusively located in
cytoplasm and expressed at a much higher level in AI
PCa cells than in AD PCa cells. In theory, the cvTBLR1
could be the product of alternative splicing, alternative
translation or proteolytic cleavage. However, it is very
interesting that when we stably overexpressed full length
TBLR1 cDNA, PCa cells also showed increased presence
of cvTBLR1. This provided evidence against formation
of cvTBLR1 by alternate splicing and evidence for posttranslational formation. Due to cvTBLR1 pro-proliferative
and anti-apoptotic roles, stable overexpression of TBLR1
may lead to selective pressure on cells to increase
formation of cvTBLR1. This appears to be a slow
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Figure 3: Function of cvTBLR1. (A) Overexpression of cvTBLR1 using nuclear export sequence (NES) fused cvTBLR1 (AA89-

514) construct to create LNCaP –NEScvTBLR1 cells. (B) Caspase 3/7 luciferase assay measuring apoptosis in LNCaP pBabe and
LNCaP NEScvTBLR1 cells in hormone free media. (C) Caspase 3/7 luciferase assay measuring apoptosis in LNCaP pBabe and LNCaP
NEScvTBLR1 cells in 150 µM bicalutamide media. (D) Quantification of the percentage of TUNEL-positive cells of LNCaP pBabe
vs. LNCaP NEScvTBLR1 cells in hormone free media. (E) Quantification of the percentage of TUNEL-positive cells of LNCaP pBabe
vs. LNCaP NEScvTBLR1 cells in 150 µM bicalutamide media. (F) Cellular proliferation comparison of LNCaP pBabe vs. LNCaP
NEScvTBLR1 cells over 6 days by CCK-8 assay. (G) Migration assay of LNCaP-NEScvTBLR1 compared to LNCaP pBabe control.
(H) Invasion assay of LNCaP-NEScvTBLR1 compared to LNCaP pBabe control and representative pictures of membrane.
www.impactjournals.com/oncotarget
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Finally, we identified a NES for cytoplasmic
localization of TBLR1 at the N-terminus which
contains two conserved leucine residues. By targeting
these sites, we may be able to develop approaches to
switch the cellular localization, thus the functions of
TBLR1.
In conclusion, TBLR1 appears to be a
multifunctional protein important for many cellular
processes. In this study, we demonstrate that cytoplasmic
TBLR1 is increased in CRPC cells. We also identify a
novel TBLR1 variant that is potentially a proteolytic
product, higher in CRPC, and promotes growth, invasion,
and antiapotosis. Both full length and and cvTBLR1 may
play a pivotal role in castration resistance of PCa. It will
be of great interest to investigate the TBLR1 cytoplasmic
forms in CRPC in the future.

the Siah-1/Siah interacting protein/Ebi-mediated
degradation pathway. Ebi(ΔF), which lacks the F-box
domain and retains ability to bind β-catenin, is capable of
preventing the Sial-induced downregulation of β-catenin
and TCF/LEF1 activity [31]. cvTBLR1 also lacks the
N-terminal F-box like region of full length TBLR1.
Given the high structural similarity between cvTBLR1
and Ebi(ΔF), the overexpression of cvTBLR1 in AI PCa
cells suggest that cvTBLR1 may function as a dominant
negative form to inhibit β-catenin degradation and thus
induce cytoplasmic accumulation of β-catenin and TCF/
LEF activity. Further, it was shown that TBL1/TBLR1
can bind β-catenin and the interaction is required for its
translocation into the nucleus [11]. It is of great interest
to investigate the link between cvTBLR1 and β-catenin
and TCF/LEF1 pathway in future studies.
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Figure 4: Identification of TBLR1 localization sequences by deletion mutation analysis. (A) Diagram of GFP-TBLR1

mutant constructs designed and summary of primary localization of transfected GFP fusion mutant construct. (B–E) Fluorescence image,
Hoescht stain, and merged image of 293T cells transfected with GFP-TBLR1 mutant constructs N2, N7, wild type, and mutant L81A.
(F–M) Quantification of TBLR1 localization observed in 293T cells transfected with mutant GFP-TBLR1 constructs.  Cells showing GFP
expression by fluorescent imaging were counted as cytoplasmic, nuclear, or both for expression.
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MATERIALS AND METHODS

without TMPP labeling or Edman degradation for
N-terminus analysis were performed as above except
after clarification and before addition of antibody NaCl
was added to bring final NaCl concentration to 300 mM
to further purify immunoprecipitate. Protein gels for
mass spectrometry were stained with Novex colloidal
blue staining kit (Invitrogen) per manufacturer’s
intructions. For Edman degradation, protein gels were
transferred to PVDF membrane as described previously
[33], as membranes were stained by colloidal blue
staining kit (Invitrogen). Protein transferred to PVDF
was analyzed by automated Edman degradation in
the Protein Structure Core Facility, University of
Nebraska Medical Center, using a Procise 494 protein
sequencer (ABI). All reagents were purchased from Life
Technologies.

Cell culture
LNCaP, LNCaP-AI, PC-3, and 293T cells were
maintained in complete medium (RPMI medium 1640
(High glucose DMEM for 293T) plus 10% FBS),
androgen-free medium (phenol-free RPMI medium with
charcoal-treated FBS), or androgen media (androgen-free
medium with 10 nM R1881). LNCaP-AI, an androgenindependent derivative of LNCaP, was from the laboratory
of Dr. A. Ferrari (New York University Cancer Institute)
[32]. LNCaP, PC-3, and 293T cells were procured from
ATCC (Manassas, VA, USA) with documentation of
authentication by STR analysis. Passages from 5 to 20 of
each cell line were used for experiments. Cell lines were
maintained at 37°C with 5% CO2. All cell culture materials
were ordered from Life Technologies.

TMPP labeling and mass spectrometry of
TBLR1

Whole cell lysates, cell fractionation, and
immunoblot analysis

Excised gel bands were reduced, alkylated and
dried. Protein was then digested with trypsin (Promega)
overnight at 37°C. Digested peptides were extracted,
desalted and analyzed by LC-MS/MS (Q Exactive,
Thermo Electron). Raw data were used to search with
Mascot Distiller a small custom database containing 176
protein sequences including TBLR1. Protein N-terminal
identification was performed as described in [34]. Ten
microliters of 0.1 M of (N-succinimidyloxycarbonylmethyl) tris (2, 4, 6-trimethoxyphenyl) phosphonium
bromide (TMPP-Ac-OSu) (Sigma) in acetonitrile were
added to gel pieces and incubated overnight. Protein was
then digested with trypsin in TEAB buffer (Promega)
overnight at 37°C. Digested peptides were extracted,
desalted and analyzed by LC-MS/MS (Q Exactive,
Thermo Electron). Raw data were searched without
enzyme restriction.

Whole-cell extracts were prepared from LNCaP,
LNCaP-AI, and PC-3 cells in RIPA buffer (50 mM TrisHCl ph 8.0, 150 mM NaCl, 1% NP-40, 1 mM EDTA,
0.1% SDS). For cell fractionation, cells were lysed with
cytoplasmic buffer (10 mM HEPES ph 7.6, 50 mM NaCl,
0.5 M sucrose, 1 mM DTT, 5 mM MgCl2, 0.1% Triton
X-100). After centrifugation, the supernatant was the
cytoplasmic fraction and the nuclear pellet was washed
3 times with cytoplasmic buffer followed by lysis with
RIPA buffer. Extracts were subjected to electrophoresis
on SDS/PAGE and then transferred to nitrocellulose
membranes for immunoblot analysis as described [33].
Antibodies for TBLR1#1 (sc-100908) were purchased
from Santa Cruz antibodies. Antibodies for H2B and
GAPDH were purchased from Cell Signaling. Antibodies
for TBLR1#2 (ab24550) and TBLR1#3 (ab84141) were
purchased from Abcam.

Construction of retroviral pBabe vectors
expressing NESTBLR1 or NEScvTBLR1 to
construct stable cell lines

Protein purification and edman degradation
Initial immunoprecipitation of TBLR1 was
performed with three separate antibodies described
above. Cells were lysed with 50 mM Tris pH 8.0,
150 mM NaCl, 1 mM EDTA, 0.5% NP-40 buffer for
20 minutes on ice. Lysates were clarified by centri
fugation for 20 minutes at 13000 rpm at 4°C. Clarified
lysates were incubated with 2 µg of TBLR1 or IgG
control antibody overnight at 4°C, followed by addition
of 20 µl Dynabeads Protein G (Invitrogen) washed with
lysis buffer for 4 hours at 4°C. Immunoprecipitated
material was washed 4× with lysis buffer and eluted
with 2× Laemmli buffer at 37°C for 5 minutes.
Large scale 50 kDa TBLR1 isoform purification by
immunoprecipitation for mass spectrometry with and
www.impactjournals.com/oncotarget

A TBLR1 fusion protein was created in which the
strong NES (MLQKKLEELE) was fused to the N terminus
of TBLR1 to create NESTBLR1. An additional fusion
protein was created in which the strong NES was fused to
the sequence of AA89-514 from full length TBLR1 to create
NEScvTBLR1. Both fusion proteins were cloned into the
pBabe Puro retroviral vector as described previously [19].
Briefly, Phoenix A amphotropic packaging cells (American
Type Culture Collection) were transfected with NESTBLR1,
NEScvTBLR1 and pBabe retroviral constructs to produce
virus. The virus-containing supernatant was collected by
centrifugation and filtered before retroviral infection. Stable
cell lines were selected in 1 µg/mL puromycin.
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Apoptosis assays

to the medium and cells were incubated for 20 min at
20– 25°C. Fluorescent images of live cells were obtained
with a Zeiss LSM710 confocal microscope imaging
system and analyzed with ImageJ software.

Promega luciferase Apoptosis was measured
by Caspase-GLO 3/7 assay (Promega) on cells after
treatment with 150 µm bicalutamide or DMSO control
for 30 hours or hormone free or 10 nM R1881 for
72 hours. Luciferase readings were read on Berthold
Lumat LB 9507. The TUNEL assay was performed using
Click- iT® TUNEL Alexa Fluor® Imaging Kit (Invitrogen)
in accordance with the manufacturer’s protocol. In
brief, cells were fixed with 4% paraformaldehyde in
PBS at room temperature for 20 min and permeabilized
with Triton X-100 (0.25% in PBS) for another 20 min.
The cells were washed twice and incubated with
terminal deoxynucleotidyl transferase reaction buffer
(Component A) for 10 min at room temperature. The
buffer was removed and the TUNEL reaction mixture
containing terminal deoxynucleotidyl transferase was
added, incubating the cells in a humidified chamber at
37°C for 60 min. Then, cells were washed three times
with 3% BSA in PBS for 2 min each and then incubated
with Click-iT reaction mixture (containing Alexa 488
azide) for 30 min at room temperature, while being
protected from light exposure. The cells were again
washed with 3% BSA in PBS and the cell nuclei were
counterstained with Hoechst 33342 for 15 min at room
temperature, protected from light. The coverslips were
washed twice with PBS before mounting onto a slide
with mounting medium. The TUNEL-positive cells were
counted in eight different, random fields for each well.

Enumeration of percentage of cells for nuclear
and cytoplasmic localization
293T cells were seeded in three wells of a 4 well
chamber slide (155382, Thermo Fisher Scientific) and
transfected with 0.5 ug DNA of GFP-TBLR1 constructs
in triplicate. At 24 hr, subcellular localization of TBLR1
and mutants was examined with a Nikon Eclipse TS100
fluorescent microscope and a Nikon DXM1200F digital
camera. A minimum of 100 cells per well were recorded
from each of three wells. Localization in each individual
cell was determined based on comparison of intensities
between cytoplasmic and nuclear GFP, and therefore
categorized into nuclear expression, cytoplasmic
expression and both nuclear and cytoplasmic expression.
Percentage of cells in each category was calculated.
Results are expressed as mean + standard error.

Growth, migration, and invasion assays
For growth assay, cells were seeded in 24 well
plates at 1 × 104 cells/well. Cell growth was monitored
every 2 days by addition of 50 µl of CCK-8 reagent
(Sigma Life Sciences) to the well, incubated at 37°C
for 1 hour and absorbance was measured at 450 nm.
For migration and invasion assays, cells (5 × 104) were
plated into Corning Biocoat Matrigel invasion chambers
or chambers with no matrigel for migration in triplicate
without serum. 10% FBS media was used as an attractant
in the lower chamber and cells were incubated for
24 hours. Membranes were fixed, washed and stained
with a Three Step Stain Kit (Richard-Allan Scientific)
and three representative regions of each membrane were
counted under the microscope.

Deletion and site-directed mutagenesis
TBLR1 C-terminus deletions (N1, N2, N3, N4, N5,
N6 and N7), N-terminus deletions (C1, C2, C3, C4, C5,
C6, C7 and C8), and both terminus deletions (M1 and
M2), were generated by PCR and cloned into pCR2.1TOPO vectors (TOPO TA Cloning kit, 450641, Life
Technologies). These deletions were then subcloned into
pcDNA3.1 (+) with GFP plasmid. pcDNA3.1 TBLR1
point mutations (Mut1, Mut2 and Mut3) were generated
using QuickChange II XL Site-Directed Mutagenesis
Kit (200521, Stratagene). Mut1 is Leu81Ala, Mut2 is
Leu83Ala and Mut3 is Leu81&83Ala. QuickChange II XL
was also used to create TBLR1 M88A mutant construct.
The list of primers used to generate these clones in
Supplementary Table 1.

Statistical analysis
Statistical analyses of the above results were
performed by pairwise Student’s t test. Differences are
considered statistically significant if p < 0.05.
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